| 14.33 -0.39 (-2.65%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.73 | 1-year : | 18.47 |
| Resists | First : | 15.18 | Second : | 15.82 |
| Pivot price | 14.96 |
|||
| Supports | First : | 14.15 | Second : | 11.78 |
| MAs | MA(5) : | 14.9 |
MA(20) : | 14.89 |
| MA(100) : | 14.69 |
MA(250) : | 15.21 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.3 |
D(3) : | 59.8 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 19.5 | Low : | 11.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ HCM ] has closed below the lower bollinger band by 12.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ HCM ] is to continue within current trading range. It is unclear right now based on current values. 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.85 - 14.92 | 14.92 - 14.99 |
| Low: | 14.32 - 14.41 | 14.41 - 14.5 |
| Close: | 14.55 - 14.7 | 14.7 - 14.84 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Sat, 28 Feb 2026
HUTCHMED (NASDAQ:HCM) Stock Crosses Below 50 Day Moving Average - Here's What Happened - MarketBeat
Wed, 25 Feb 2026
Understanding Momentum Shifts in (HCM) - Stock Traders Daily
Tue, 24 Feb 2026
HUTCHMED (China) Limited (HCM) Stock Analysis: Unpacking a 39% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Tue, 24 Feb 2026
HUTCHMED (LON:HCM) Share Price Crosses Below 200 Day Moving Average - Here's Why - MarketBeat
Fri, 06 Feb 2026
HUTCHMED to Announce Final Results for 2025 on March 5, 2026 - Quiver Quantitative
Fri, 06 Feb 2026
HUTCHMED to Announce 2025 Final Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 172 (M) |
| Held by Insiders | 5.0908e+008 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 633.29 |
| Profit Margin | 77.5 % |
| Operating Margin | -1.3 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | 46.9 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 1.03385e+008 |
| Sales Per Share | 1.15808e+009 |
| EBITDA (p.s.) | -1.44038e+007 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | 5.43 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | 5.23 |
| Dividend | 0 |
| Forward Dividend | 315470 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|